18 results about "Bifidobacterium bifidum" patented technology

The application provides a coffee peel enzyme fermentation agent and a preparation method of the enzyme, and belongs to the technical field of enzyme production.The preparation method of the coffee peel enzyme comprises the following steps: mixing coffee peel powder and sugar of sweetener oil residue, and sequentially performing fermentation of Saccharomyces cerevisiae YNXC003 and anaerobic fermentation of Bifidobacterium bifidum YNXC004 to obtain the coffee peel enzyme.The coffee peel powder and the sugar of sweetener oil residue are used as composite raw materials, special bacterial agents are combined, and a segmented fermentation mode is adopted, so that the nutritional activity of the two raw materials can be fully released, the nutritional level and flavor taste of the enzyme can be significantly improved, and the enzyme can be endowed with physiological functions such as blood sugar reduction.The total acid content of the coffee peel enzyme is 8-12 g / L, the total phenol content is 1.5-2.5 g / L, the coffee peel enzyme is rich in bioactive substances such as short-chain fatty acids, polyphenol compounds and amino acids, and has a significant blood sugar reduction effect.

The application provides bifidobacterium longum MG-G763 for improving constipation, and belongs to the technical field of microorganisms. The bifidobacterium longum MG-G763 provided by the application can effectively relieve constipation by integrating multiple effects such as nerve regulation, immune regulation, barrier repair and flora regulation, and systematically restoring intestinal function homeostasis. The bifidobacterium longum MG-G763 can significantly improve the defecation particle number and defecation weight of constipated mice, shorten the time for defecating the first black stool, improve the small intestinal transport rate of the mice, effectively improve and relieve the defecation condition of the constipated mice, and significantly increase the amount of intestinal beneficial bacteria and reduce the amount of harmful bacteria, thereby promoting intestinal health.

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

This chronic kidney disease progression inhibitor utilizes Bifidobacterium bifidum as an active ingredient. As a result, present invention provides an agent that is more effective by using a bacterial strain that is different from hitherto-reported bacteria that belong to the genus Bifidobacterium and that have been used against chronic kidney diseases.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium bifidum PlantBase-931 for removing dampness and aiding weight loss, its fermented products, preparation methods, and applications. Bifidobacterium bifidum PlantBase-931 can increase the levels of GAS and MTL in the blood, strengthen the spleen and stomach, promote the expression of AQP3 and AQP4 in colon tissue, and accelerate the elimination of dampness from the body, thus benefiting obese individuals in their weight loss journey. The PlantBase-931 fermented product is prepared by staged fermentation, spray drying, and vacuum freeze-drying of the composition. The composition consists of the following ingredients in parts by weight: navel orange, hawthorn, grape, lychee, papaya, coix seed, winter melon, white sugar, and purified water. The resulting fermented product can reduce IL-1β inflammation levels in the spleen, repair spleen damage, and improve loose stool symptoms in obese individuals.

This invention provides a coffee pericarp enzyme, its specific compound fermentation agent, and a preparation method, belonging to the field of enzyme production technology. The preparation method of the coffee pericarp enzyme of this invention includes the following steps: mixing coffee pericarp powder with sacha inophyllum pomace saccharides, and sequentially subjecting the mixture to fermentation with *Saccharomyces cerevisiae* YNXC003 and anaerobic fermentation with *Bifidobacterium bifidum* YNXC004 to obtain the coffee pericarp enzyme. This invention uses coffee pericarp powder and sacha inophyllum pomace saccharides as compound raw materials, combined with a specific fermentation agent, and employs a segmented fermentation mode. This not only fully releases the nutritional activity of the two raw materials, significantly improving the nutritional level and flavor of the enzyme, but also endows the enzyme with physiological functions such as lowering blood sugar. The total acid content of the coffee pericarp enzyme of this invention is 8-12 g / L, the total phenol content is 1.5-2.5 g / L, and it is rich in short-chain fatty acids, polyphenolic compounds, amino acids, and other bioactive substances, exhibiting significant blood sugar lowering effects.

This invention discloses a probiotic composite hydrogel with colonic mucosal targeting function, its preparation method, and its applications. The hydrogel uses thiolated sodium alginate and catechin-modified chitosan as a matrix, constructing a dual network structure through calcium ion-mediated ionic crosslinking and covalent crosslinking to encapsulate Bifidobacterium bifidum Z29-2. The hydrogel exhibits excellent mucosal adhesion and intestinal retention capacity, demonstrating good probiotic protection and sustained-release characteristics in simulated gastrointestinal fluid. The microspheres with 2.5% calcium ion crosslinking exhibit regular morphology and dense structure, significantly prolonging intestinal retention time. The composite hydrogel constructed in this invention combines protective, targeting, and sustained-release functions, can regulate mucin glycosylation, and enhance the intestinal barrier, showing promising application prospects in the field of intestinal microecological therapy.

This invention relates to the field of biomedical detection technology, specifically to plasma circulating microbial biomarkers for early screening of gastric cancer and their applications. The plasma circulating microbial biomarkers include: *Ralstonia solanacearum*, *Staphylococcus aureus*, *Alternaria metachromatica*, *Porphyromonas gingivalis*, *Lactobacillus reuteri*, *Rhodococcus erythropolis*, *Akkermansia muciniphila*, *Lactobacillus gasseri*, *Bifidobacterium bifidum*, and *Neisseria gonorrhoeae*. This invention screens and, for the first time, combines 10 specific microbial biomarkers with Low Pass technology. WGS technology can achieve detection results at low depths, significantly reducing screening costs while ensuring detection sensitivity, and providing a brand-new solution for early gastric cancer screening.

The present invention provides combinations of microbial flora selected from the group consisting of Phascolactobacterium faecium, Phascolactobacterium succinatus, Dialister succinatus, Dialister propionysifaciens, Bifidobacterium bifidum, and Lactobacillus intestinalis for use in succinate consumption, processes for producing such combinations, their compositions, and uses.

The present invention relates to novel lactic acid bacteria, Lactococcus lactis P32 (KCCM13222P), Bifidobacterium bifidum P45 (KCCM13223P), or a mixture thereof, and uses thereof. Strains and a mixture thereof, according to the present invention, can be effectively used in the prevention or treatment of an inflammatory disease, osteoporosis, depressive disorder, or anxiety disorder.

This invention discloses a respiratory health preparation of *Lactobacillus acidophilus* that enhances the mucosal barrier, relating to the field of microbial preparation technology. The preparation includes probiotic active ingredients and a pharmaceutically or food-grade acceptable carrier. The probiotic active ingredients consist of *Lactobacillus acidophilus* LH-001, *Lactobacillus rhamnosus* LR-002, and *Bifidobacterium bifidum* BB-003, which have been selectively adapted for respiratory use. It also includes synergistic functional components. By weight, the synergistic functional components include 1-5 parts of 2'-fucosylated lactose, 0.5-2 parts of low-molecular-weight sodium hyaluronate, and 0.1-0.5 parts of baicalin. The weight-average molecular weight of the low-molecular-weight sodium hyaluronate is 10-30 kDa. This invention obtains three functionally complementary exclusive strains through selective respiratory adaptation, and, combined with the synergistic effect of the synergistic components and targeted formulation technology, solves the problems of poor compatibility and difficult live bacteria delivery of conventional intestinal strains, achieving in-situ efficacy in the respiratory tract and meeting the needs of multiple commercial dosage forms.

The invention discloses a primer probe combination for detecting various bifidobacteria and application of the primer probe combination, and belongs to the field of molecular biological detection. The primer probe combination provided by the invention comprises a primer probe group for detecting bifidobacterium breve, a primer probe group for detecting bifidobacterium bifidum and a primer probe group for detecting bifidobacterium adolescentis. Based on the primer probe combination, the invention respectively develops a single PCR detection method and a triple PCR detection method for detecting the three bifidobacteria. Experimental results show that the detection method provided by the invention can be used for accurately detecting bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis. According to the invention, a foundation is laid for authenticity identification of products containing bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis, and a more convenient method is provided for detection of bifidobacterium breve, bifidobacterium bifidum and bifidobacterium adolescentis.

Bifidobacterium bifidum CANM183 and extracellular vesicles thereof are applied to avoid intestinal injury and promote intestinal health. The application discloses application of Bifidobacterium bifidum CANM183 or extracellular vesicles thereof with a preservation number of CGMCC NO. 35416 in preparation of products for promoting intestinal health and avoiding intestinal injury. After oral delivery, the specific particle size extracellular vesicles derived from the strain can actively antagonize physical attacks caused by harmful pathogenic bacteria and harmful pathological vesicles secreted by the harmful pathogenic bacteria in a local microenvironment of the intestine, significantly improve a transmembrane resistance value of intestinal epithelial cells, and up-regulate continuous expression of a tight junction protein in situ to efficiently repair a damaged intestinal physical barrier. In addition, the natural antibacterial substances enriched in the extracellular vesicles can accurately inhibit abnormal proliferation of conditional pathogenic bacteria, reshape intestinal microecological genus level structure, and silence excessive expression of local pro-inflammatory cytokines in the colon, so that a new deep targeted intervention strategy and exact material basis are provided for improving microecological imbalance and avoiding intestinal pathological injury from the most upstream source of macromolecular penetration blocking.

The application discloses a bifidobacterium qis1821 with high indole-3-lactic acid yield and application thereof, and is characterized by being classified and named as bifidobacterium qis1821 Bifidobacterium bifidum , and is preserved in the China General Microbiological Culture Collection Center on May 13, 2026, with a preservation number of CGMCC No. 38669. The bifidobacterium qis1821 has the application in the preparation of high-yield indole-3-lactic acid products and antioxidants, and also has the application in the preparation of intestinal flora regulators. The bifidobacterium qis1821 has the characteristics of high indole-3-lactic acid yield, good tolerance in an artificial gastric juice and antioxidant performance, and can also produce lactic acid and other beneficial metabolites, so that the intestinal flora can be regulated, and the intestinal mucosal barrier function can be enhanced.

This invention discloses the application of Bifidobacterium bifidum in anti-atherosclerosis and promoting energy metabolism, belonging to the field of microbial technology. Bifidobacterium bifidum (… Bifidobacterium bifidum NHNK-618 was deposited at the China Center for Type Culture Collection on August 9, 2024, with accession number CCTCCNO:M20241761. NHNK-618 possesses functions such as inhibiting atherosclerosis-related pathogens, promoting vascular endothelial cell relaxation, reducing vascular endothelial adhesion and oxidative damage, improving energy metabolism in hepatic and renal cells, reducing fat accumulation in hepatocytes, and inhibiting high-energy-accumulation-related pathogens. It can enhance the body's overall energy utilization efficiency through multi-organ synergy and multi-target regulation, and thus can be used to prepare products for anti-atherosclerosis and energy metabolism promotion.

A composition for treating insomnia, comprising a probiotic complex and traditional Chinese medicine components. The probiotic complex comprises Lactobacillus plantarum, Bifidobacterium lactis, Lactobacillus crispatus, Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Lactobacillus reuteri, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus fermentum, Lactobacillus gasseri, Lactococcus lactis, Bifidobacterium longum, Lactobacillus salivarius, Bifidobacterium breve, Streptococcus thermophilus, Lactobacillus paracasei and Lactobacillus helveticus. The traditional Chinese medicine components are semen ziziphi spinosae, bulbus lilii, poria, semen nelumbinis and mori fructus. The composition may further comprise prebiotics selected from L-arabinose, β-glucan, inulin, erythritol, lactitol, vitamin C and γ-aminobutyric acid. The composition can be used for preparing pharmaceutical or food formulations, such as solid beverages, chewable tablets or oral lozenges. Clinical observation shows that the composition has the effect of relieving insomnia.

This invention discloses a method for preparing and applying an energy-saving and environmentally friendly straw roughage, relating to the field of feed preparation technology. The preparation method includes the following steps: S1, weighing 5-20 parts by weight of corn straw powder, 5-20 parts of pearl millet, 5-20 parts of whole corn, 10-30 parts of wheat straw, 5-20 parts of locust tree leaf powder, and 1-10 parts of tree leaves and branches, and mixing them to obtain a primary feed; S2, adding a mixed microbial culture to the primary feed, wherein the mixed microbial culture includes at least *Lactobacillus plantarum* and *Bifidobacterium bifidum*; S3, adding a mold inhibitor and basic feed to the roughage containing the mixed microbial culture, and anaerobic fermenting at 35°C to produce fermented roughage. The energy-saving and environmentally friendly straw roughage preparation method according to this invention can utilize waste resources, saving energy and protecting the environment; it can also fatten edible livestock, and feeding animals with microbially fermented feed can improve their disease resistance, reduce antibiotic use, and improve meat quality.